AstraZeneca PLC, which is more reliant on the Chinese market than its multinational peers in terms of share of China-derived revenue within the total, sees its China business as on track for a return to growth, despite price reductions resulting from the country’s drug price negotiation since March.
In the first half ended 30 June, the UK-based major’s China sales rose 7% year-over-year to $3.0bn, accounting for 14%...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

